VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex Inc. (NASDAQ: VERX) has unveiled a new survey showcasing the critical role of automation and digital transformation in ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity was originally published by The Motley Fool ...

ROI is in the forecast – 49% say they expect to achieve ROI through better forecasting and decision-making, closely followed by a more cost effective and future proofed technology architecture and a ...

On Monday, Vertex Inc (VERX) stock saw a decline, ending the day at $49.29 which represents a decrease of $-2.70 or -5.19% from the prior close of $51.99. The stock opened at $50.35 and touched a low ...

Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...

Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and welcome to the Vertex Inc. Third Quarter 2024 ...

Vertex's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle. Read my ...

Hello and thanks for joining us to discuss Vertex Inc third quarter financial results. I'm Joe Crivelli, Vice President, Investor Relations, David DiStefano, our President and CEO and John Schwab. Our ...